Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Total 13F shares
-
22,891,685
-
Share change
-
-1,264,969
-
Total reported value
-
$68,903,436
-
Price per share
-
$3.01
-
Number of holders
-
34
-
Value change
-
-$4,060,912
-
Number of buys
-
16
-
Number of sells
-
21
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2019
As of 30 Sep 2019,
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,891,685 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, BVF INC/IL, Novo Holdings A/S, PRICE T ROWE ASSOCIATES INC /MD/, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, DIMENSIONAL FUND ADVISORS LP, and FMR LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.